IGBA Makes Access Pact With WHO

Promotes The Use Of Generics And Biosimilars

24 Oct 2019

The WHO has taken an “important first step” towards increased collaboration with the generics and biosimilars industries through an agreement with the IGBA to promote access to medicines, including working towards a reduced trial burden for biosimilars and speeding up registration for both generics and biosimilars.

Pills_World_Map — The global agreement will promote access to generics and biosimilars • Source: Shutterstock

A pact has been struck between the World Health Organization and the International Generic and Biosimilar Medicines Association that the WHO says “highlights the role of the pharmaceutical industry in helping WHO maintain tools that can facilitate registration of generic and biosimilar medicines.”

The memorandum of understanding – which the WHO described as “an important first step towards increased collaboration with the generic...